Figure 2
Structure of the model. AE: adverse event, PL: platelet, SP: splenectomy, RO: romiplostim, RI: rituximab. The model is composed of six states. Each cycle was a 28-day period. The cycle starts from the idiopathic thrombocytopenic purpura (ITP) treatment state (PL <30 × 109/L) and moves to the next state after 28 days. However, if PL remains <30 × 109/L after the treatment, the cycle remains at the ITP treatment state. The broken line shows the flow of patients treated with splenectomy and rituximab, i.e., patients who received treatments other than romiplostim.